Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin professional labeling cardiovascular indications final rule in works.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN PROFESSIONAL LABELING CARDIOVASCULAR INDICATIONS FINAL RULE will incorporate the June 1996 FDA proposal on aspirin professional indications and recommendations for additional claims made by the agency's Nonprescription Drugs and Cardiovascular & Renal Drugs Advisory Committees at a meeting last January. FDA Division of OTC Drug Evaluation Director Debra Bowen, MD, indicated at an Aug. 28 "feedback" meeting that the final rule is nearing completion and has begun to circulate through the agency for review.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel